WINNIPEG, MB – February 20, 2025 – Cytophage Technologies (‘Cytophage’ or ‘the Company’) (TSXV: CYTO; FSE: 70G) is honoured to announce that it was named Bioscience Company of the Year by the Bioscience Association Manitoba (‘BAM’). This recognition celebrates Cytophage’s pioneering advancements in bacteriophage technology, including groundbreaking developments in human phage therapy, animal health solutions, and food security applications.

BAM’s prestigious award acknowledges Cytophage’s commitment to combatting antimicrobial resistance (‘AMR’) through innovative, sustainable, and scalable phage-based solutions. Over the past year, the Company has achieved key milestones: Cytophage went public on the TSX-V, and celebrated the grand opening of its new, 20,000-square-foot manufacturing facility and office headquarters. Cytophage’s phage therapy was also successfully used in a human patient in Ontario, and the Company recently announced the expansion of its poultry product trials.

“We are proud to recognize Cytophage Technologies as this year’s Bioscience Company of the Year. Their work exemplifies the kind of innovation and leadership that makes Manitoba a hub for cutting-edge bioscience research and commercialization,” said Andrea Ladouceur, President and CEO of BAM.

Cytophage will be officially recognized at BAM’s Industry Celebration Dinner on March 12, 2025, where government and industry leaders, researchers, and innovators will gather to celebrate Manitoba’s thriving bioscience sector.

“This award is a testament to our team’s dedication to solving one of the most pressing global health challenges—antimicrobial resistance. We believe phage technology is the future, and we are committed to bringing phage solutions to market in a way that is scientifically rigorous, commercially viable, and globally scalable,” said Dr. Steven Theriault, CEO of Cytophage.

About Cytophage 
 
Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. 

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature’s version of antibiotics. 

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products. 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

About the Bioscience Association of Manitoba

Bioscience Association Manitoba (BAM) is a not-for-profit industry association that enables commercial success for Manitoba’s bioscience companies by acting as a catalyst for innovation, expanding the sector’s skills and workforce development, and leading with one unified voice to create local and global engagement.

For further information please contact:  

Heather Medwick, Chief Operating Officer 
heather@cytophage.com | 431 388 8873 

For media inquiries, please contact: 
Simon Bredin, PR Advisor (media@cytophage.com)  

Cautionary Statement on Forward-Looking Information 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.